GSK plc (NYSE:GSK) agreed to acquire IDRx, Inc., a biopharmaceutical company focused on precision therapeutics for gastrointestinal stromal tumors (GIST), for $1 billion. Under the agreement, GSK ...

Chinese drugmaker Jiangsu Hengrui Pharmaceuticals has agreed to develop up to 12 of its drugs with British pharmaceutical giant GSK. Hengrui Pharma granted GSK an exclusive worldwide licence to its ...

GSK has agreed to buy US biopharmaceutical business IDRx in a deal worth up to $1.15billion (£1billion). Under the agreement, GSK will pay $1billion upfront to acquire the Massachusetts-based firm, ...

May 13 (Reuters) - Britain's GSK (GSK.L), opens new tab and drug developer iTeos Therapeutics (ITOS.O), opens new tab said on Tuesday they have stopped developing an experimental lung cancer drug, ...

GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion. By Rebecca Robbins The British drug maker GSK said on Wednesday that it ...

A lot of focus around reducing hallucinations has been applied during the training of a large language model (LLM), or when it is learning from data. But to mitigate hallucinations, GSK instead ...

Partnership is integral to GSK. Bringing people together is the best way to innovate and deliver products that transform the standard of care and improve lives. Over half of GSK’s clinical vaccine ...

GSK Buys Asthma Drug Developer For Up To $1.4 Bn By AFP - Agence France Presse Jan 09, 2024, 4:46 am EST Share ...

GSK Plc and iTeos Therapeutics ended the development of an experimental lung cancer drug, the latest in a series of setbacks for a new generation of immunotherapy medicines. Interim analysis from two ...

Biopharmaceutical company GSK is growing its Massachusetts work force, announcing plans to move its vaccines research and development and infectious disease teams from suburban Maryland to Cambridge ...